4.4 Article

Effects of different delivering matrices of β-glucan on lipids in mildly hypercholesterolaemic individuals: a meta-analysis of randomised controlled trials

Journal

BRITISH JOURNAL OF NUTRITION
Volume 125, Issue 3, Pages 294-307

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0007114520001610

Keywords

beta-Glucan; Total cholesterol; LDL; Hyperlipidaemia; Meta-analyses

Funding

  1. National Natural Science Foundation of China [81872618]
  2. Postgraduate Research& Practice Innovation Programof Jiangsu Province [KYCX19_0121]
  3. Scientific Research Foundation of Graduate School of Southeast University [YBPY1944]

Ask authors/readers for more resources

A meta-analysis found that consuming >= 3 g/d of beta-glucan for at least 3 weeks can significantly reduce total cholesterol and LDL-cholesterol levels in mildly hypercholesterolaemic individuals, with no significant effects observed on TAG and HDL-cholesterol. Incorporating beta-glucan into both 'solid products' and 'liquid products' was found to be the most effective way to exert its beneficial properties.
beta-Glucan has been reported for its health benefits on blood lipids in hypercholesterolaemic individuals for years. However, people have paid little attention to the effects of beta-glucan in populations with mild hypercholesterolaemia as well as the various delivering matrices. Our objective was to perform a meta-analysis to analyse the effects of beta-glucan with different delivering matrices in mildly hypercholesterolaemic individuals. After conducting a comprehensive search in Web of Science, PubMed, Scopus and Cochrane Library, a total of twenty-one randomised controlled trials involving 1120 participants were identified to measure the pooled effect. The overall results indicated that consuming a dose of >= 3 g/d of beta-glucan for at least 3 weeks could significantly reduce total cholesterol (TC) (-0 center dot 27 mmol/l, 95 % CI -0.33, -0.21, P < 0.001) and LDL-cholesterol (-0.26 mmol/l, 95% CI -0.32, -0.20, P < 0.001) compared with the control group in mildly hypercholesterolaemic individuals, while no significant difference was observed in TAG (-0.03 mmol/l, 95% CI -0.11, 0.06, P = 0.521) and HDL-cholesterol (0.01 mmol/l, 95% CI -0.03, 0.04, P = 0.777). There was evidence for modest unexplained heterogeneity in the meta-analysis. In conclusion, beta-glucan can significantly reduce risk factors like TC and LDL-cholesterol for CVD in mildly hypercholesterolaemic individuals; furthermore, it appears that the effects of food matrices with both 'solid products' and 'liquid products' where beta-glucan was incorporated into were ranked as the best way to exert its beneficial properties, while 'liquid' and 'solid' products were ranked as the second and third positions, respectively.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available